Joint Formulary & PAD

Guideline Profile : Rheumatoid arthritis

Committee Recommendations (1)

The Surrey Heartland Integrated Care System Area Prescribing Committee have agreed the SERMOG Rheumatoid Arthritis high-cost drugs pathway.

Guideline Profile

Indication :
Rheumatoid arthritis
Keywords :
Abatacept, adalimumab, etanercept, anakinra, baricitinib, certolizumab, golimumab, infliximab, rituximab, tocilizumab, sarilumab, tofacitinib, upadacitinib, filgotinib, penicillamine, prednisone, sodium aurothiomalate, RA, Immunomodulator, Protein Kinase Inhibitor, JAK inhibitor, Janus Kinase, NICE TA, JAKI, anti-TNF, TNF alpha, b-cell, IL 6, interleukin inhibitor, biosimilar, biologic, SERMOG, RA-ILD
Brand Names Include :
MabThera, Truxima, Rixathon, Ruzience, Orencia, Humira, Hyrimoz, Imraldi, Amgevita, Hulio, Yuflyma, Idacio, Kineret, Olumiant, Cimzia, Enbrel, Benepali, Erelzi, Jyseleca, Simponi, Remicade, Inflectra, Remsima, Flixabi, Zessly, Distamine, Lodotra, Kevzara, Myocrisin, RoActemRA, Tyenne, Xeljanz, Rinvoq, Ituxredi
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Supporting Documents :
3